Participants 126 165 6
A follow-up of 212 randomized patients.
Participants 167 292 7
Two hundred and twelve patients treated for prostatic cancer grade I or II were investigated for cardiovascular complications
Participants 294 494 5
The patients were part of a multicentre study in the Stockholm area and had been randomized to treatment with either estramustine phosphate (Estracyt) or polyestradiol phosphate and ethinyl estradiol.
